IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 1, December 2025
Impact Factor: 7.67

Cyclophosphamide in Transplant Immunology: Mechanistic Precision, Immune Reprogramming, and Toxicity

Miss. Sakshi Vijay Khandare, Dr. Avinash S. Jiddewar, Asst. Pranit G. Kubare
Miss. Vaishnavi D. Dhokane, Miss. Shivam B. Waghamare
NSPM College of Pharmacy, Darwha, Yavatmal

Abstract: *Cyclophosphamide is an alkylating prodrug widely used as an immunosuppressant in oncology, autoimmunity and transplantation. Its immunomodulatory efficacy stems from hepatic bioactivation to DNA-alkylating metabolites that preferentially damage proliferating lymphoid populations, modulate T-cell subsets, and alter regulatory networks involved in allograft rejection. Recent work highlights dose- and timing-dependent effects: high-dose, peri-transplant cyclophosphamide depletes alloreactive T cells and prevents graft-versus-host disease (GVHD) in hematopoietic stem cell transplantation, while low-dose regimens exert selective effects on regulatory T cells and myeloid-derived suppressor cells with potential to reshape tolerance induction. Cyclophosphamide's therapeutic window is constrained by predictable toxicities — myelosuppression, hemorrhagic cystitis, gonadal injury, cardiotoxicity and infection risk — whose incidence depends on cumulative dose, metabolite exposure, and host pharmacogenetics (CYPs, POR). Balancing efficacy and toxicity requires regimen optimization (dose, schedule, mesna hydration), pharmacogenetic awareness, and combination strategies with targeted agents (calcineurin inhibitors, MMF, PTCy schedules). This review synthesizes mechanistic, pharmacologic, clinical-trial, and toxicity data to inform rational use of cyclophosphamide in organ transplantation*

Keywords: Cyclophosphamide, Immunosuppression, Post-transplant cyclophosphamide (PTCy), Organ transplantation, T-cell modulation, Toxicity, CYP2B6, Clinical trials, Tolerance induction

I. INTRODUCTION

Cyclophosphamide (CPA) has been used clinically since the 1950s and remains a cornerstone alkylating immunosuppressant in both hematologic and solidorgan contexts. As a prodrug, CPA requires hepatic activation by cytochrome P450 enzymes to yield 4-hydroxycyclophosphamide and downstream phosphoramide mustard — the DNA alkylating species responsible for cytotoxicity. Historically developed as an anticancer agent, CPA's capacity to suppress both humoral and cellular immunity was rapidly exploited for autoimmune diseases and transplant medicine, where it has contributed to induction, desensitization, and graft-tolerance strategies. In the transplant field, CPA plays roles across settings: pre-transplant conditioning, induction therapy for highly sensitized or HLA-mismatched recipients, and post-transplantation cyclophosphamide (PTCy) regimens to prevent graftversus-host disease in bone-marrow and increasingly in solid-organ and haploidentical contexts. Importantly, CPA's immunologic effects are not simply cytotoxic; depending on dose and timing it can selectively deplete rapidly proliferating alloreactive effector T cells, transiently spare or even expand regulatory populations, and reshape innate-myeloid suppressive compartments — features that lend CPA unique utility in tolerance induction. These beneficial immune effects occur alongside a predictable toxicity profile — myelosuppression and infectious risk, urotoxicity (hemorrhagic cystitis), gonadal dysfunction, and cardiotoxicity — that constrains dosing and long-term use. Recent decades have therefore focused on optimizing CPA regimens (dose, timing, mesna prophylaxis, hydration), understanding pharmacogenetic determinants of activation (CYP2B6, CYP2C19; POR), and combining CPA with targeted immunomodulators to maximize graft

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 1, December 2025 Impact Factor: 7.67

protection while minimizing harm. This review integrates mechanistic biology, pharmacology, clinical trial evidence, and toxicity mitigation strategies to support evidence-based CPA use in transplantation. [1][4][27].



II. IMMUNOSUPPRESSIVE MECHANISM OF CYCLOPHOSPHAMIDE

Overview

Cyclophosphamide is a nitrogen mustard prodrug requiring hepatic bioactivation to exert cytotoxic and immunomodulatory effects. Key mechanistic layers include (1) bioactivation/metabolism, (2) DNA-alkylation leading to apoptosis of proliferating lymphocytes, (3) differential effects on T-cell subsets (effector vs regulatory), (4) effects on antigen-presenting and myeloid populations, and (5) induction of peripheral tolerance through selective depletion of alloreactive clones and homeostatic immune reconstitution. [4][11][26].



Stepwise mechanism

1. **Hepatic activation** — CPA is hydroxylated by hepatic cytochrome P450 enzymes (notably CYP2B6 and CYP2C19, with contributions from other CYPs and POR) to form 4hydroxycyclophosphamide (4-OHCP), in equilibrium with its tautomer aldophosphamide. Aldophosphamide is further converted to phosphoramide mustard (the DNA-alkylating moiety) and acrolein (a toxic metabolite). The rate of activation and metabolite profile is modulated by genetic polymorphisms and induction/inhibition of CYP enzymes, affecting both efficacy and toxicity. [4][15][10].
2. **DNA crosslinking and cytotoxicity** — phosphoramide mustard forms inter- and intra-strand DNA crosslinks in dividing cells, triggering cell cycle arrest and apoptosis. Lymphocytes, particularly activated and proliferating allo-reactive T cells responding to donor antigen, are highly sensitive. This results in rapid depletion of effector T cells in the peritreatment window. [6][20].
3. **Selective effects on T cell subsets** — dosing and timing determine relative effects: high-dose post-transplant CPA (PTCy) given after graft infusion preferentially eliminates rapidly proliferating alloreactive

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 1, December 2025
Impact Factor: 7.67

conventional T cells while sparing quiescent or slowly dividing regulatory T cells (Tregs) and hematopoietic stem cells, thereby reducing graftversushost processes and promoting immune regulation. Conversely, lowdose CPA has been shown to transiently deplete Tregs in some cancer contexts but can also induce immune-regulatory shifts dependent on schedule. These differential subset effects underpin CPA's use both to reduce alloreactivity and to modulate tolerance. [0][26][27].

4. **Myeloid and innate immune modulation** — CPA influences myeloidderived suppressor cells (MDSCs) and antigen-presenting cells; some regimens increase suppressive myeloid populations that contribute to tolerance, while others may transiently impair antigen presentation and cytokine responses. The net result is remodeling of both adaptive and innate compartments during reconstitution. [11][22].
5. **Homeostatic reconstitution and tolerance induction** — after depletion, immune recovery proceeds under altered conditions (reduced alloreactive clones, relative preservation/expansion of Tregs and tolerogenic myeloid cells), enabling the establishment of longer-term tolerance or reduced rejection risk when combined with other agents (calcineurin inhibitors, MMF, tacrolimus, etc.). The timing of CPA relative to antigen exposure (e.g., post-graft administration) is central to harnessing this reconstitution for tolerance. [27][12].

III. FLOW CHART

Cyclophosphamide (prodrug)

↓

(hepatic P450 activation: CYP2B6, CYP2C19; POR modifies)

4- Hydroxycyclophosphamide⇄Aldophosphamide

↓

(decomposition)

Phosphoramide mustard (active; DNA-alkylator) + Acrolein (urotoxic)

↓

DNA crosslinking → apoptosis of dividing cells

↓

Effects on immune compartments:

- Rapid depletion: proliferating effector T cells (↓ alloreactivity)
- Relative sparing/preservation: quiescent Tregs & stem cells (→ tolerance) - Myeloid shifts: MDSC changes, reduced APC activation

↓

Homeostatic reconstitution → Potential tolerance (if combined/optimized) (References for pathways and subset effects). [4][6][26][27].

IV. CLINICAL TRIALS

Historical context and transplant uses

Cyclophosphamide has broad historical use in transplantation: induction in solidorgan recipients (to prevent acute rejection), treatment of rejection episodes, and conditioning in hematopoietic stem cell transplantation (HSCT). More recently, post-transplantation cyclophosphamide (PTCy) used at relatively high single doses after grafting has dramatically improved GVHD prophylaxis and enabled successful haploidentical HSCT by eliminating alloreactive T cells while allowing immune reconstitution. These clinical successes from HSCT have prompted evaluation of PTCy approaches in solid-organ and other transplant settings. [5][8][7]. Key clinical trial evidence

1. **PTCy in HSCT** — Fundamental trials and cohort series established PTCy (typically 50 mg/kg on days +3 and +4 post-transplant) as effective for GVHD prevention in haploidentical transplants and comparably effective in matched transplants when combined with calcineurin/tacrolimus and MMF. NEJM and multiple multicenter trials have shown reductions in severe acute GVHD and acceptable relapse/overall survival rates in diverse HSCT populations. [8][19].

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 1, December 2025 Impact Factor: 7.67

2. **PTCy dose-optimization** — Recent trials have investigated reduced or split dosing to limit toxicity while preserving efficacy. Early phase studies report that adjusted dosing retains GVHD prophylaxis with lower hematologic toxicity in selected cohorts; randomized data are emerging. Translational studies support that timing (post-graft) is crucial for selective depletion of alloreactive T cells. [28][27].
3. **Solid-organ transplant trials** — CPA has been used in desensitization protocols for highly sensitized kidney transplant candidates (to reduce circulating anti-HLA antibodies) and in select induction regimens for cardiac and renal transplants historically. Results were mixed historically due to toxicity; more contemporary trials focus on targeted low-dose or singledose perioperative strategies integrated with modern immunosuppressants. Evidence suggests potential benefit in select highrisk patients but underscores toxicity concerns. [21][12].
4. **Comparative and registry data** — Large registries and systematic reviews show that PTCy improves GVHD outcomes without clear increases in relapse in many cohorts; however, heterogeneity in conditioning regimens, donor types, and concomitant immunosuppression means that generalizability requires careful interpretation. Observational data from centers using PTCy in non-haploidentical and matched donors show expanding applicability but also highlight the need for randomized comparisons in specific transplant populations. [16][25].

Efficacy endpoints and biomarkers

Clinical endpoints in trials include incidence and severity of acute and chronic rejection/GVHD, infection rates, relapse (for malignant indications), graft/patient survival, and quality of life.

Biomarkers used in translational substudies include lymphocyte subset kinetics (effector/regulatory T cells), chimerism in HSCT, donor- specific antibody levels in solid-organ transplantation, and pharmacokinetic/metabolite monitoring of CPA and active metabolites. Pharmacogenetic markers (CYP2B6 variants, POR expression) have been correlated with variable metabolic activation and clinical outcomes in some cohorts, suggesting that personalized dosing strategies could improve therapeutic index. [4][10][15].

Safety and toxicity in trials

Clinical trials consistently report predictable hematologic toxicity (neutropenia, thrombocytopenia), with infection as a major sequela; urotoxicity (hemorrhagic cystitis) rates vary by cumulative dose and prophylaxis (mesna, hydration); gonadal dysfunction and secondary malignancy risk are dose-dependent longterm concerns. Cardiotoxicity is uncommon but associated with very high doses. Modern trial protocols routinely use mesna and hydration, dose adjustments, and supportive care to mitigate these risks. Several systematic reviews of CPA toxicity across indications confirm these patterns and recommend mitigation strategies incorporated into trial protocols. [3][14][23].

Ongoing questions and active trials

Active and recent trials are exploring (a) refined PTCy schedules in matched donor HSCT and solidorgan contexts, (b) lower-dose or split-dosing PTCy to reduce myelotoxicity while preserving immunologic benefits, (c) CPA combinations with targeted biologics to reduce cumulative toxicity, and (d) pharmacogenetically guided dosing. Results from randomized controlled studies will be critical to define standardized CPA regimens across transplant types. [28][17].

V. TOXICITY, TOLERANCE, AND RISK– BENEFIT BALANCE

Cyclophosphamide's clinical value in transplantation is defined by a narrow therapeutic index: sufficient bioactivation and exposure are required to deplete alloreactive lymphocytes and permit tolerance, yet metabolite formation (notably acrolein) and systemic DNA-alkylation produce predictable toxicities. Achieving an optimal balance demands attention to dosing strategy, timing relative to antigen exposure, metabolite management, pharmacogenetics, and synergistic combinations.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 1, December 2025
Impact Factor: 7.67

Dose and timing: the central tradeoff

PTCy exploits a timing-dependent window: high-dose CPA administered shortly after graft infusion targets proliferating donor-reactive host (or donor) T cells that have entered cell cycle after antigen encounter, sparing quiescent stem and regulatory compartments. This approach maximizes immunologic benefit (reduced GVHD) while limiting prolonged marrow toxicity because the singledose posttransplant avoids chronic exposure. Conversely, repeated or continuous high cumulative CPA dosing increases bone-marrow suppression, infection risk, and off-target organ damage. Low-dose or metronomic CPA regimens have distinct immunologic signatures (selective Treg depletion or modulation) that may be exploited for desensitization or adjunctive immune modulation, but their net benefit in transplantation depends on precise scheduling and combination with other agents. Therefore, regimen design must align the immunologic objective (deplete effectors vs modulate regulators) with dosing and timing to minimize unnecessary exposure. [27][26][8].

Metabolite toxicity and uroprotection

A major toxicity driver is acrolein, a urinary metabolite that causes hemorrhagic cystitis. Standard mitigation uses mesna (mercaptoethane sulfonate) to bind acrolein in urine and vigorous hydration and frequent voiding to reduce bladder exposure. Trials and clinical practice consistently show mesna prophylaxis dramatically reduces clinically significant hemorrhagiccystitis, enabling safer use of high-dose CPA. Monitoring and early intervention for hematuria/pathologic urinary findings are standard. [3][23].

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 1, December 2025 Impact Factor: 7.67

Pharmacogenetics and pharmacokinetics

Inter-individual variability in CPA activation (CYP2B6, CYP2C19) and in enzymes modulating oxidative metabolism (POR) influences both efficacy and toxicity. Patients with slower activation may receive inadequate cytotoxic exposure, risking suboptimal immunosuppression; ultra-rapid activation may elevate toxic metabolites and toxicity risk. Several studies correlate CYP2B6 genotype/phenotype variation with outcome metrics. Integrating pharmacogenetic testing into pre-transplant assessment could allow dose tailoring — an attractive approach to improve therapeutic index but one requiring prospective validation.

Pharmacokinetic monitoring of CPA and 4-OHCP in trial settings has been feasible and might support individualized dosing. [4][10][15].

Combination therapy to reduce cumulative toxicity

Combining single- or limited-dose CPA with targeted immunosuppressants (e.g., tacrolimus + MMF after PTCy) can maintain graft protection while allowing lower cumulative CPA exposure. The PTCy backbone plus calcineurin/antimetabolite maintenance is now common in HSCT protocols. In solid-organ transplantation, combining lower-dose CPA with modern induction agents and antibody therapies may achieve desensitization or induction without high cumulative CPA doses, reducing long-term gonadal or secondary malignancy concerns. Combination strategies should be evaluated in randomized settings to determine whether they permit safe CPA de-escalation without loss of efficacy. [8][16][12].

Toxicity monitoring and mitigation

Routine measures to mitigate CPA toxicity include:

Mesna + aggressive hydration to prevent hemorrhagic cystitis. [3][23].

Hematopoietic growth factor support (G-CSF) for prolonged neutropenia where indicated. [14].

Fertility counseling and gonadal protection strategies (sperm banking, oocyte preservation) prior to high cumulative dosing. [1].

Cardiac monitoring for regimens employing very high doses. [3].

Patient selection and risk stratification

Balancing efficacy and toxicity requires evaluating baseline infection risk, marrow reserve, prior chemo exposures, renal function (affecting excretion), and fertility considerations. Patients with high immunologic risk (haploidentical donors, highly sensitized recipients) may derive disproportionate benefit from aggressive PTCy regimens, justifying certain toxicity tradeoffs, whereas lowerrisk patients may be better served by reduced CPA exposure combined with targeted immunosuppression. Incorporating pharmacogenetic data, prior cumulative exposures, and patient preferences is necessary for individualized decision-making. [10][16].

Future directions to improve therapeutic index

Pharmacogenetically guided dosing to match activation capacity. [4][10].

Refined PTCy schedules (dose-splitting or lower single doses) to reduce marrow toxicity while maintaining immunologic selectivity. [28].

Adjunct targeted agents to allow CPA de-escalation (e.g., checkpoint modulation, costimulation blockade) while preserving tolerance. [11][26].

In sum, rational CPA use in transplantation is a multidimensional optimization problem combining pharmacology, genetics, regimen design, and supportive care to preserve immune benefit while minimizing short- and long-term toxicity.

VI. CONCLUSION

Cyclophosphamide remains a versatile immunosuppressant in transplantation, uniquely capable of selectively eliminating alloreactive lymphocytes when used with optimized timing (PTCy) and appropriate supportive measures. Maximizing benefit while minimizing harm requires regimen tailoring, pharmacogenetic awareness, uro-protective

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 1, December 2025 Impact Factor: 7.67

measures, and combination strategies. Ongoing trials and personalized approaches promise to refine CPA's therapeutic index in transplant practice. [8][4].

REFERENCES

[1]. MH, StatPearls. Cyclophosphamide. NCBI Bookshelf. 2023;4,16
[2]. Ahlmann M, Hempel G. The effect of cyclophosphamide on the immune system. 2016;3,4.
[3]. Fraiser LH. Cyclophosphamide toxicity: characterising and avoiding the... 1991;12,16.
[4]. Helsby NA et al. The importance of CYP2C19 and CYP2B6 germline... 2019;8,14,16.
[5]. Majzner RG et al. Post-Transplant Cyclophosphamide after Bone Marrow... 2017;9.
[6]. Winkelstein A. Effects of Cyclophosphamide on Cellular Immunity. 1973;6,8.
[7]. Al-Homsi AS. Post-Transplant High-Dose Cyclophosphamide for the... 2015;9.
[8]. A Bolaños-Meade J et al. Post-Transplant Cyclophosphamide–Based GraftVersus-Host. NEJM. 2023;9,14,15.
[9]. Alrefaei AE et al. Cyclophosphamide related toxicity; a systematic review. IJMDC 2022;4.
[10]. Mangó K et al. Association between CYP2B6 genetic variability and... Sci Rep. 2023;5,11,14.
[11]. Swan D et al. Beyond DNA Damage: Exploring the Immunomodulatory... Hemasphere. 2020;5,7.
[12]. Takeuchi A et al. Cyclophosphamide-induced tolerance in kidney... 2018;10,15.
[13]. Ngo D et al. Strategies to Minimize... (review). 2022;11,12.
[14]. Fraiser LH. Cyclophosphamide Toxicity | Drugs (detailed review). 1991;12,15 .
[15]. El-Serafi I et al. Cytochrome P450 Oxidoreductase Influences CYP2B6 Activity... PLoS ONE. 2015;11,14.
[16]. Marco-Ayala J et al.Impact of Post-Transplantation Cyclophosphamide on... 2023;11,15,16 .
[17]. Al Malki MM et al. PTCy-based GVHD prophylaxis: JCO 2025 abstract. JCO/ASCO 2025;12.
[18]. Helsby NA. Which CYP2B6 variants have functional consequences. 2012/2013;8,13.
[19]. Majzner RG et al. Post-Transplantation Cyclophosphamide after Bone Marrow... ASTCT journal 2017;9
[20]. Namdaroglu S et al. Impacts of post-transplantation cyclophosphamide ... Sci Rep 2019;6.
[21]. Nunes NS, Kanakry CG. Mechanisms of Graft-versus-Host Disease Prevention by Posttransplantation Cyclophosphamide: An Evolving Understanding. Frontiers in Immunology, 2019;2,5.
[22]. Wachsmuth LP, et al. Mechanism of action of posttransplantation cyclophosphamide: more than meets the eye. JCI, 2019;7.
[23]. JADPRO. Post-Transplant Cyclophosphamide for the Prevention of GVHD: A Guide to Management. 2023;12,15.
[24]. PTCy + Tacrolimus / Mycophenolate study (HLA-matched donor PBSC transplant) — longterm immunosuppression outcomes.
[25]. Post-transplantation cyclophosphamide expands functional myeloid-derived suppressor cells (MDSCs) and indirectly influences Tregs.
[26]. Post-transplant cyclophosphamide–induced cardiotoxicity: a comprehensive review.
[27]. Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression. PMC study (murine model).
[28]. Pharmacokinetic (PK) exposure of 4-hydroxycyclophosphamide correlates with clinical benefit in reduced-dose PTCy (Phase I/II trial).
[29]. Kidney outcomes in PTCy-based regimens: PTCy associated with lower longterm CKD compared to calcineurin inhibitors.
[30]. KARA & Elibol. High-dose PTCy in matched sibling donor transplant. Namık Kemal Med Journal, 2021.
[31]. Strauss G, Emadi A, review from JADPRO PDF on mechanism (apoptosis, ALDH, Tregs) in PTCy.
[32]. Frontiers Immunology review on CPA biology and PTCy, with emphasis on cell-cycle, Fas, Treg sparing.
[33]. Poster abstract: PTCy + abatacept + vedolizumab to prevent GVHD after HSCT.
[34]. UC Irvine thesis / report on cyclophosphamide immunosuppression, T-cell sensitivity, and stem-cell resistance.